Management of Bladder Cancer: The First Inning of a New Era of Rapid advances

The management of bladder cancer has witnessed several multidisciplinary advances in the past few years (Fig. 1). This issue of the Hematology/Oncology Clinics of North America takes the reader on an exciting journey highlighting the recent advances. Metastatic urothelial carcinoma (mUC) is generally incurable. Cisplatin-based combination chemotherapy yields a median survival of 14 to 15 months…

Read the full article here

Related Articles